cyrilzakka/clinical-trials huggingface dataset:
Conditions of Diagnostic Panendoscopy of the Upper Airway Under Propofol Remifentanil General Anesthesia

The most important considerations for the general anesthesia in diagnostic panendoscopy of the upper airway is the maintenance of a patient's airway for optimal surgical exposure, adequate ventilation and sufficient depth of anesthesia. Tubeless anesthestic techniques with preserved spontaneous ventilation and total intravenous administration of anesthetic drugs are widely use. Due to its pharmacological profile, propofol anesthesia is often considered as the gold standard for the anesthesia in the diagnostic panendoscopy. Previous studies suggested that adding remifentanil to propofol could improve the conditions for laryngoscopy and tracheal intubation.

The aim of this study is to assess the impact of propofol remifentanil general anesthesia compared to propofol general anesthesia on the conditions of the diagnostic panendoscopy of the upper airway.


Eligibility Criteria:
Inclusion Criteria:

* Elective diagnostic panendoscopy of the upper airway
* Age \> 18 and \< 80 years old
* American Society of Anesthesiology (ASA) score equal to 1, 2, or 3 with a stable condition
* Written inform consent

Exclusion Criteria:

* Pregnancy or breastfeeding
* Age \< 18 years old or inability to give informed consent
* Known anaphylaxis to remifentanil or propofol
* Long term opioid use, drug abuse
* Predictive criterion of impossible mask ventilation or intubation
* Chronic respiratory failure requiring oxygen therapy
Automated Breast Ultrasound as an Adjunct to Screening Digital Breast Tomosynthesis

The purpose of this study is to assess whether the Invenia™ Automated Breast Ultrasound (ABUS) device, as an adjunct to Digital Breast Tomosynthesis (DBT), improves breast cancer detection in women with dense breasts. The study aims to collect information about cancer detection, treatment, and outcomes based on individual and combined technologies in patients who receive ABUS exams in addition to DBT. The results of this study are intended to be used to extend understanding of ABUS as an adjunct in DBT screening in patients with dense breasts.

Following consenting procedures, subjects will undergo standard of care DBT of both breasts or of one breast if they have had prior uni-lateral mastectomy. Subjects will also undergo ABUS of both breasts or of one breast if they have had prior uni-lateral mastectomy. These imaging exams will be done per the sites routine practice, and can be done in any order.

Images will be read and assessed by one (1) Mammography Quality Standards Act (MQSA)-qualified reader. The evaluating radiologist will use the image reconstruction views appropriate for the evaluation, per his or her medical judgment, and handle diagnostic evaluations in accordance with the standard of care at the investigational site. The DBT images will be read and assessed first and independent of ABUS images. DBT plus ABUS will then be read per routine practice and assessed. Images will not be read until both imaging exams have been completed.

If screening shows a suspicious finding, subjects will receive standard of care follow-up and appropriate workup, which may include biopsy (as needed), to determine cancer status. Subjects will be followed at approximately one year (11- to 16-months) unless negative histopathology with image concordance or positive cancer status is histologically determined prior to one-year follow-up. Follow up procedures will be conducted as per the sites standard of care.

Eligibility Criteria:
Inclusion Criteria:

1. Are asymptomatic adult women (aged 40 years or older);
2. Are presenting for a DBT breast cancer screening exam;
3. Have heterogeneously dense or extremely dense breasts (BI-RADS C or D)
4. Are able and willing to participate.

Exclusion Criteria:

1. Have been previously included in this study;
2. Have undergone diagnostic or surgical intervention in the last 12 months, including, but not limited to, core or open biopsy, clip placement, fine-needle aspiration, cytopunction, breast reduction or reconstruction, implant removals; OR
3. Have had a breast cancer diagnosis or treatment in the past 12 months and have re-entered the screening population.
Comparison Study of Intraoperative Patient Warming Systems

Medications used to put people to sleep during surgical procedures also cause changes in the body's ability to control its temperature. These changes can make a person's temperature drop below normal. To minimize this drop in body temperature, different types of body warming products are used during surgery. This study is designed to compare the the temperatures of people under general anesthesia after 60 minutes of warming with each product. The study hypothesis is that the people warmed with the Dynatherm Medical vitalHEAT vH2 System will decrease less in the first 60 minutes of warming time than people warmed with the Arizant Bair Hugger System.


Eligibility Criteria:
Inclusion Criteria:

* Pts undergoing orthopedic surgical procedure with expected duration 2-3 hrs
* General anesthesia required
* ASA physical status I-III

Exclusion Criteria:

* General anesthesia plus epidural anesthesia required
* Skin abrasions/trauma to extremity selected as application site
* History of peripheral vascular disease
* History of malignant hyperthermia
* Unwilling/unable to give consent
Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction

to findout the improvement by Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction


Eligibility Criteria:
Inclusion Criteria:

* ● Age between 25-40

  * Both males and females included
  * Participants suffering from recent cervical pain without any pathology.

Exclusion Criteria:

* ● Participants having cervical radiculopathy

  * Having recent trauma of the cervical spine
  * Non-cooperative subject
Topical Finasteride in the Treatment of Idiopathic Hirsutism

the purpose of this study is to evaluate the efficacy of topical Finasteride in the treatment of idiopathic hirsutism


Eligibility Criteria:
Inclusion Criteria:

* Idiopathic hirsutism which is defined as normal levels of androgens and normal ovulation
* Normal serum prolactin

Exclusion Criteria:

* Pregnancy
* Simultaneous use of other drugs for the treatment of hirsutism
Femoral Triangle Block: Early Mobilization and Postoperative Analgesia After Total Knee Arthroplasty

The objective of this trial is to compare the efficacy of three different nerve blocks as an analgesic option after total knee arthroplasty (TKA), based on muscle strength, mobilization and pain.

The Adductor Canal Block has been proposed as an equally effective technique to the Femoral Nerve Block in terms of pain control after a TKA, with the benefit of preserving muscle function. We hypothesize that a block performed at the apex of the femoral triangle would best balance analgesia with quadriceps function.


Eligibility Criteria:
Inclusion Criteria:

* Subjects of any gender, from 18 to 90 years old that accept to participate in the study.
* Programmed primary total knee arthroplasty surgery

Exclusion Criteria:

* Emergent surgery
* Reinterventions
* Unstable psychiatric pathology, dementia
* Kidney or hepatic disease that contraindicates the use of NSAIDs and/or Paracetamol.
* Allergy to amides local anesthesics, NSAIDs, opioids and/or Paracetamol.
* Daily use of opioids greater than 30 mg of morphine (or equivalent)
* Patients under 18 or over 90 years old.
* Drug abuse
* Rejection to be a participant of the study.
DP13 - A Phase II Study in Patients With Primary Aldosteronism

The purpose of the present phase II study is to determine whether DP13 displays the clinical safety and efficacy profile to support further development in patients with primary aldosteronism.

A phase II, multi-centre, randomized, parallel group, baseline-and withdrawal-controlled study in patients with primary aldosteronism to determine the dose-dependent efficacy, safety and tolerability of DP13 after a 2-week single-blind placebo run-in period followed by a randomized 8-week double-blind treatment period. After an additional single-blind, 2-week DP13 placebo withdrawal period, patients are switched to standard of care.

Eligibility Criteria:
Inclusion Criteria:

Patients with a guideline-recommended diagnosis of primary aldosteronism

Exclusion Criteria:

Patients with primary aldosteronism and

* hyperkalemia
* prolonged QT intervals
* refusal of special contraception measures
DNA Damage and Oxidative Stress in Hospitalized COVID-19 Patients

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic challenging health systems worldwide.

While there is a clear correlation between oxidative stress markers and the severity of many viral diseases such as hepatitis C, for SARS-CoV clinical data is limited.

The investigators aim at 1.) investigating DNA damage, oxidative stress, inflammation, and aging markers in COVID-19 patients and compare them with age and gender matched healthy controls and patients with influenza; and 2.) investigating all aforementioned parameters during "cytokine storm" via repeated blood sampling.


Eligibility Criteria:
Covid 19 group:

Inclusion Criteria:

* gender: female/male
* age: ≥40 years
* patients admitted at the emergency department
* COVID-19 suspected patients
* able to give written informed consent

Exclusion Criteria:

* children (≤ 18 years) and adults 19-39 years
* not hospitalized, but confirmed COVID-19 patients (outpatients)
* patients without definitive COVID-19 confirmation

Control group:

Inclusion criteria:

* gender: female/male
* age: ≥40 years
* absence of severe illnesses/serious diseases
* able to give written informed consent

Exclusion criteria:

* children (≤ 18 years) and adults 19-39years
* any current or past clinically significant pathology/disease (comorbidity) such as:

  * Malignancies
  * Cardiovascular diseases
  * Diabetes mellitus (I and II)
  * Obesity class III (BMI \>40)
  * Other severe diseases (e.g. renal, hepatic, thyroid disease, bone metabolic diseases, rheumatoid osteoarthritis, human immunodeficiency syndrome, ...)

Influenza group:

Inclusion criteria:

* gender: female/male
* age: ≥40 years
* patients admitted at the emergency department
* influenza suspected patients
* able to give written informed consent

Exclusion criteria:

* children (≤ 18 years) and adults 19-39 years
* patients without definitive influenza confirmation
Evaluate Safety and Efficacy of Autologous Bone Marrow-derived Endothelial Progenitor Cells in Advanced Liver Cirrhosis

Endothelial Progenitor Cells (EPC) represent a small cellular population of bone marrow and peripheral blood cells. EPCs are recruited into injured tissues and play an important role in regeneration and reparation. Experimental and clinical data suggest that EPCs have hepatoprotective activity and could improve liver regeneration during acute and chronic liver injury. The aim of this project is to evaluate the safety and therapeutic effects of autologous bone marrow-derived EPCs, when administered through the hepatic artery of patients with advanced liver cirrhosis.


Eligibility Criteria:
Inclusion Criteria:

* Liver cirrhosis (Child-Pugh 8 or above).
* Ability to sign informed consent

Exclusion Criteria:

* Age \<18 or \>75
* Variceal bleeding or severe infection within the past 30 days before screening
* Chronic encephalopathy preventing the ability to sign informed consent (it could be done by legal representant of the patient) and/or the ability to follow the study protocol
* Hepatocellular carcinoma (previous or current)
* Any current or previous malignancy (within 5 years before the inclusion) except "in situ" tumors or skin basal cell carcinomas
* Any severe extrahepatic disease during the past 30 days before the inclusion
* Any current decompensated chronic disease
* Any contraindication for the examinations of the clinical protocol (medullar aspiration, arteriography, HVPG measurement)
* Any other condition that could negatively affect the compliance with the protocol
* Pregnant or breast-feeding women
* Participation in a trial of an experimental drug or device within 30 days before screening
A Study for Teriparatide in Severe Osteoporosis

This observational study will evaluate the incidence of new vertebral and non vertebral fragility fractures in patients with severe osteoporosis treated with anabolic drugs. This study will also evaluate BMD, compliance to treatment, back pain and the health-related quality of life.

The participants should be treated with anabolic therapy for osteoporosis (Teriparatide or PTH 1-84) for 18 months and should be followed up for subsequent 6 months. The treatment is expected to improve bone mineral density, back pain and reduce the risk of new fractures due to osteoporosis. The outcomes will be evaluated by bone densitometry at the lumbar spine and femoral neck, by standard radiographs, by measurements of bone formation marker (P1NP) and by questionnaires on back pain and quality of life. Postmenopausal women and men over 21 years old may be included if they have:

1. at least 3 severe vertebral fractures
2. 2 severe vertebral fractures and 1 hip fracture
3. an incidental vertebral fracture or an hip fracture during treatment with antiresorptives prescribed for at least 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal women and men older than 21 years affected by severe osteoporosis with an incidental vertebral or hip fracture during treatment with an antiresorptive, or having 3 or more severe vertebral fractures or having 2 severe vertebral fractures and an historical hip fracture.

Exclusion Criteria:

* Any contraindication for the use of antiosteoporotic drug
* Premenopausal women or men younger than 21 years
Is the Preoperative Preparation of Sickle Cell Patients Optimal: Assessment of Practices and Post-operative Complications

Children with sickle cell disease systematically receive a transfusion 2 to 5 days before scheduled surgery (with the exception of minor surgeries) in order to avoid post-operative complications of which the vaso-occlusive crisis and acute thoracic syndrome are the most frequent.

This standardized preoperative protocol was established on the basis of the results of large-scale randomized studies, most of which date back over ten years, and which have demonstrated the beneficial effects of transfusion (or transfusion exchange) preoperatively. To date, several other more recent studies (but not controlled) have questioned this type of systematic management.

The purpose of this study is to review retrospectively data of sickle cell children who have undergone elective surgery at the Huderf in the last ten years and to identify the eventual complications encountered. The most common procedures in these patients are: tonsillectomy with or without associated adenoids, splenectomy and cholecystectomy.

General data on sickle cell disease (history, genotype, G6PD deficiency, biology and previous complications), pre-surgical preparation, surgery and post surgical management and complications will be collected and analyzed.

This retrospective analysis will allow an objective assessment of the current quality of care and will provide useful data to improve patient management.


Eligibility Criteria:
Inclusion Criteria:

* Sickle cell disease with surgery during the 2010-2019 period

Exclusion Criteria:

* None
Multidimensional Assessment of Dyspnea in Asthma

Breathlessness is a symptom of asthma that occurs in relation with lower airway obstruction. However, this sensation is not specific of asthma and may be the expression of other disorders. In particular, it can testify to anxiety or hyperventilation, two disorders frequently associated with asthma. The systematic interpretation of dyspnea as a manifestation of asthma in asthmatic patients may lead to an inappropriate increase in asthma controllers.

Identifying the cause of dyspnea in asthmatic patients (airway obstruction, anxiety or hyperventilation) is therefore crucial for the clinician.

This could be facilitated by a multidimensional assessment of dyspnea, evaluating the kind of sensation felt by the patient (for example chest tightness, air hunger etc.) and emotions associated to respiratory sensations (for example anxiety, fear etc.).

The objectives of this project are to assess: (1) the sensory and affective dimensions of dyspnea in asthma and, (2) their connection to asthma control, anxiety and depression.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of asthma confirmed by:

   * A history of symptoms compatible with asthma
   * AND a history of airway obstruction, according to the GINA definition (2017): FEV1/FVC ratio lower than the lower limit of the predicted value at baseline or after a bronchial provocation test
   * AND a variability of airway obstruction defined by at least one of the following criteria:

   oReversibility of airway obstruction after bronchodilators (400 µg of salbutamol): FEV 1 increases by\> 200 mL and\> 12% compared to baseline
   * OR delta peak-flow over the day / average peak-flow averaged over 2 weeks\> 10%
   * OR variability in FEV1 between two visits\> 200 mL and\> 12%
   * OR an increase in FEV1 of\> 200 mL and\> 12% compared to the baseline after 4 weeks of treatment with oral corticosteroids
   * OR a positive methacholine challenge: decrease in FEV1 by more than 20% for a dose \<1600 µg
2. Experience of dyspnea in the past 7 days
3. Age\> 18 years old
4. Social protection affiliation 5. Written informed consent

Exclusion Criteria:

1. Age \<18 years old
2. Active smoker or quitting smoking for less than a year
3. Severe exacerbation or respiratory infection within 4 weeks before inclusion (severe exacerbation is defined by an increase in systemic corticosteroid therapy for at least 3 days or injection of a single dose of delayed corticosteroid, emergency room visit due to asthma (with systemic corticosteroid therapy), or hospitalization due to asthma).
4. Inability to respond to questionnaires for any reason
5. Presence of any pathology other than asthma which may be responsible for dyspnea, in particular cardiovascular or respiratory (ischemic heart disease, heart failure, chronic obstructive pulmonary disease, diffuse interstitial pneumonitis, lung cancer, non-exhaustive list) with the exception of anxiety and hyperventilation syndrome
6. Pregnancy
7. Persons under guardianship
8. Refusal to sign consent or participate in the study
9. No social protection affiliation
Ketones in Heart Failure With Reduced Ejection Fraction

The purpose of this study is to understand the effects of a ketone drink on exercise capacity and other cardiovascular parameters in patients with heart failure. In heart failure, patients are limited in their ability to do all the things they want to do, and exercise as much as they would like, due to becoming tired and short of breath early. There may be several reasons why these symptoms occur. This study is assessing whether the ketone drink can improve these symptoms. This drink has been given status by Food and Drug Administration as "generally regarded as safe".

The use of DeltaG in this study is experimental. DeltaG has not been approved by the Food and Drug Administration (FDA) for the use being evaluated in this study.


Eligibility Criteria:
Inclusion Criteria:

1. Stable cardiovascular medical therapy for 2 weeks
2. Participants will be required to have heart failure with reduced ejection fraction (left ventricular EF \</= 45%) and New York Heart Association (NYHA) class II or III symptoms.

Exclusion Criteria:

1. Intentional ketogenic diet in the last week
2. Cirrhosis or significant alcohol consumption
3. Contraindications to stress testing, conditions that limit exercise, and other clinically-significant causes of exertional limitation (claudication with peripheral artery disease, atrial fibrillation and heart rate \>110 at rest, systolic blood pressure\>180 mmHg or diastolic blood pressure\>110 mmHg, infiltrative/hypertrophic cardiomyopathy, clinically significant pericardial disease, joint or neuromuscular disease that precludes exercise, acute coronary syndrome within the last 2 months, estimated glomerular filtration rate\<20 mL/min/1.73 m2, and hemoglobin \< 9 mg/dL).
4. Clinically significant lung disease: supplemental oxygen (aside from obstructive sleep apnea), chronic obstructive pulmonary disease requiring home oxygen or exacerbation within the last 2 months requiring steroids or antibiotics, severe obstructive lung disease (Gold stage 3).
5. \>/= Moderate aortic stenosis, \>mild mitral stenosis, \> moderate aortic or mitral regurgitation
6. Type 1 diabetes mellitus
7. Implant of cardiac resynchronization therapy, cardiac contractility modulation, or barostim device within the previous 3 months.
8. Systolic blood pressure \<90 mmHg
9. Pregnant women
10. Angina due to epicardial coronary disease or known presence of clinically-significant, unrevascularized epicardial coronary disease, in the investigator's opinion.
11. History of heart transplant, left ventricular assist device, or use of inotropic medication.
12. Participation in another clinical study with an investigational product in the previous 4 weeks prior to enrollment.
13. Conditions that may render the patient unable to complete the study
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)

The goal of this study is to learn what happens to enlicitide decanoate and atorvastatin in a healthy person's body over time. Researchers want to learn what happens to enlicitide decanoate in the body when it is given with and without another medicine called atorvastatin and what happens to atorvastatin in the body when it is given with or without enlicitide decanoate.


Eligibility Criteria:
Inclusion Criteria:

* Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
* Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, standard and orthostatic vital signs, and electrocardiograms (ECGs)

Exclusion Criteria:

* History of gastrointestinal disease which may affect food and drug absorption or has had a gastric bypass or similar surgery
* History of cancer (malignancy)